Targeting fungi in combination with cancer therapy
Described herein are methods for the treatment of cancer by modulating fungal populations to enhance the therapeutic response to a cancer therapy. In particular, the present invention discloses modulating the fungal microbiome in combination with a cancer therapy to enhance the anti-tumor effect.
1. A method of treating cancer or reducing tumor size in a subject in need thereof, comprising:
administering to the subject, between one month and one day prior to initial commencement of cancer therapy treatment, a therapeutically effective amount of a composition comprising an anti-fungal agent that modulates a fungal population in the subject's gut; and
administering to the subject a therapeutically effective amount of a cancer therapy,
wherein the administration of the composition modulates a fungal population in the subject's gut and enhances the therapeutic response or anti-tumor response to the cancer therapy, and
wherein the cancer therapy is selected from the group consisting of radiation therapy (RT), chemotherapy, immunotherapy, targeted therapy and combinations thereof.
2. The method of claim 1 , wherein the cancer is breast cancer.
3. The method of claim 1 , wherein the anti-fungal agent causes a decrease in the fungal population.
4. The method of claim 3 , wherein the fungal populations decreased are Aspergillus, Cladosporium, Phoma, Guehomyces, Candida tropicalis or combinations thereof.
5. The method of claim 1 , wherein the anti-fungal agent is fluconazole, 5-flurocytosine, amphotericin B or a combination thereof.
6. The method of claim 1 , wherein the cancer therapy is RT and the RT is administered in a dosage between 2Gy to 34Gy.
7. The method of claim 6 , wherein the RT is administered for 1 to 7 weeks.
8. A method of enhancing the efficacy of a cancer therapy in a subject in need thereof, comprising:
administering to the subject, between one month and one day prior to initial commencement of the cancer therapy treatment, a therapeutically effective amount of an anti-fungal agent that modulates a fungal population in the subject's gut; and
administering to the subject a therapeutically effective amount of the cancer therapy wherein the cancer therapy is selected from the group consisting of radiation therapy (RT), chemotherapy, immunotherapy, targeted therapy and combinations thereof, and thereby enhance the efficacy of the cancer therapy in the subject.
9. The method of claim 8 , wherein the subject is a subject with breast cancer.
10. The method of claim 8 , wherein administering the anti-fungal agent and cancer therapy prolongs the delay in tumor regrowth compared to non-treated tumors.
11. The method of claim 8 , wherein the anti-fungal agent causes a decrease in a fungal population.
12. The method of claim 8 , wherein the anti-fungal agent is fluconazole, 5-flurocytosine and amphotericin B.
13. The method of claim 8 , wherein the cancer therapy is radiation therapy (RT).
14. The method of claim 1 , comprising administering, 3 weeks prior to cancer therapy treatment, the composition comprising the anti-fungal agent.
15. The method of claim 1 , comprising administering, 2 weeks prior to cancer therapy treatment, the composition comprising the anti-fungal agent.
16. The method of claim 1 , comprising administering, 1 week prior to cancer therapy treatment, the composition comprising the anti-fungal agent.
17. The method of claim 8 , comprising administering, 3 weeks prior to cancer therapy treatment, the composition comprising the anti-fungal agent.
18. The method of claim 8 , comprising administering, 2 weeks prior to cancer therapy treatment, the composition comprising the anti-fungal agent.
19. The method of claim 8 , comprising administering, 1 week prior to cancer therapy treatment, the composition comprising the anti-fungal agent.
20. The method of claim 1 , further comprising continuing to administer the composition comprising the anti-fungal agent concurrently or simultaneously with the cancer therapy.
21. The method of claim 8 , further comprising continuing to administer the anti-fungal agent concurrently or simultaneously with the cancer therapy.